Articles & insights
ABPI Code & PMCPA
UK promotional compliance under the ABPI Code of Practice and PMCPA guidance and cases.
Disclosure UK: How It Works, Deadlines, Consent and Objections
Disclosure UK explained: reportable transfers, deadlines, pre-publication review, consent, legitimate interests and recipient objections.
Read the article 2026-09-30The ABPI Signatory: Certification Requirements, Role and Training
What the 2024 ABPI Code requires of signatories: who can certify, what must be certified, notifying the MHRA and PMCPA, recertification and records.
Read the article 2026-09-30Lessons from Recent PMCPA Cases: What 2026 Rulings Mean for Your Processes
Twelve PMCPA cases completed in 2026, summarised: social media, press releases, certification, prescribing information and culture, with practical fixes.
Read the article 2026-06-02PMCPA’s 2026 Social Media Guidance: Compliance Priorities Companies Should Address Now
What the PMCPA's 2026 Social Media Guidance means for pharma: employee activity, corporate accounts, influencers and adverse event monitoring.
Read the article 2025-08-26Compliance Training: Beyond the Code
Why compliance training fails as a checkbox. Lessons from a PMCPA case on role clarity and escalation, and how scenario-based training builds ownership.
Read the articleQuestions, answered
ABPI Code & PMCPA: common questions
Who administers the ABPI Code of Practice?
The Prescription Medicines Code of Practice Authority (PMCPA) administers the ABPI Code independently of the ABPI.
When did the 2024 ABPI Code take effect?
It took effect on 1 October 2024, with a transition period to 31 December 2024. The PMCPA began operating under its new constitution and procedure, including an abridged complaints procedure, from 1 October 2024.